Endogenous urokinase lacks antifibrotic activity during progressive renal injury

American Journal of Physiology - Renal Physiology

Volumn 293, Issue 1, 2007, Pages

  Yamaguchi, Ikuyo ^b   Lopez Guisa, Jesus M ^b   Cai, Xiaohe ^b   Collins, Sarah J ^b   Okamura, Daryl M ^b   Eddy, Allison A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Renal interstitial fibrosis; Serine protease; Unilateral ureteral obstruction

Indexed keywords

CADHERIN; MESSENGER RNA; PLASMINOGEN ACTIVATOR; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SERINE PROTEINASE; UROKINASE; UROKINASE RECEPTOR; UVOMORULIN; COLLAGEN; FIBRIN; PEPTIDE HYDROLASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; DISEASE SEVERITY; EXPERIMENTAL MODEL; FIBROGENESIS; FIBROSING ALVEOLITIS; GENETIC DISORDER; HYPOTHESIS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; KIDNEY FIBROSIS; KIDNEY INJURY; MACROPHAGE; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STATISTICAL SIGNIFICANCE; URETER OBSTRUCTION; WESTERN BLOTTING; WILD TYPE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; DISEASE COURSE; ENZYMOLOGY; FIBROBLAST; FIBROSIS; GENETICS; GENOTYPE; KIDNEY; KIDNEY DISEASE; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHENOTYPE; PHOSPHORYLATION; PHYSIOLOGY;

ANIMALS; BLOTTING, WESTERN; COLLAGEN; DISEASE PROGRESSION; FIBRIN; FIBROBLASTS; FIBROSIS; GENOTYPE; HEPATOCYTE GROWTH FACTOR; KIDNEY; KIDNEY DISEASES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PEPTIDE HYDROLASES; PHENOTYPE; PHOSPHORYLATION; PLASMINOGEN ACTIVATORS; RNA, MESSENGER; URETERAL OBSTRUCTION; URINARY PLASMINOGEN ACTIVATOR;

EID: 34548030216     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00380.2006     Document Type: Article

References (33)

1. Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, De Vos R, van den Oord JJ, Collen D, Mulligan RC. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 368: 419-424, 1994.
2. Cozen AE, Moriwaki H, Kremen M, DeYoung MB, Dichek HL, Slezicki KI, Young SG, Veniant M, Dichek DA. Macrophage-targeted overexpression of urokinase causes accelerated atherosclerosis, coronary artery occlusions, and premature death. Circulation 109: 2129-2135, 2004.
3. Edgtton KL, Gow RM, Kelly DJ, Carmeliet P, Kitching AR. Plasmin is not protective in experimental renal interstitial fibrosis. Kidney Int 66: 68-76, 2004.
4. Eitzman DT, McCoy RD, Zheng X, Fay WP, Shen T, Ginsburg D, Simon RH. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 97: 232-237, 1996.
5. Fujimoto H, Gabazza EC, Taguchi O, Nishii Y, Nakahara H, Bruno NE, D'Alessandro-Gabazza CN, Kasper M, Yano Y, Nagashima M, Morser J, Broze GJ, Suzuki K, Adachi Y. Thrombin-activatable fibrinolysis inhibitor deficiency attenuates bleomycin-induced lung fibrosis. Am J Pathol 168: 1086-1096, 2006.
6. Gao X, Mae H, Ayabe N, Takai T, Oshima K, Hattori M, Ueki T, Fujimoto J, Tanizawa T. Hepatocyte growth factor gene therapy retards the progression of chronic obstructive nephropathy. Kidney Int 62: 1238-1248, 2002.
7. Hart DA, Whidden P, Green F, Henkin J, Woods DE. Partial reversal of established bleomycin-induced pulmonary fibrosis by rh-urokinase in a rat model. Clin Invest Med 17: 69-76, 1994.
8. Hattori N, Mizuno S, Yoshida Y, Chin K, Mishima M, Sisson TH, Simon RH, Nakamura T, Miyake M. The plasminogen activation system reduces fibrosis in the lung by a hepatocyte growth factordependent mechanism. Am J Pathol 164: 1091-1098, 2004.
9. Heymans S, Lupu F, Terclavers S, Vanwetswinkel B, Herbert JM, Baker A, Collen D, Carmeliet P, Moons L. Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice. Am J Pathol 166: 15-25, 2005.
10. Hu K, Yang J, Tanaka S, Gonias SL, Mars WM, Liu Y. Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. J Biol Chem 281: 2120-2127, 2006.
11. Kitching AR, Holdsworth SR, Ploplis VA, Plow EF, Collen D, Carmeliet P, Tipping PG. Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis. J Exp Med 185: 963-968, 1997.
12. Liang OD, Chavakis T, Linder M, Bdeir K, Kuo A, Preissner KT. Binding of urokinase plasminogen activator to gp130 via a putative urokinase-binding consensus sequence. Biol Chem 384: 229-236, 2003.
13. Lieber A, Vrancken Peeters MJ, Meuse L, Fausto N, Perkins J, Kay MA. Adenovirus-mediated urokinase gene transfer induces liver regeneration and allows for efficient retrovirus transduction of hepatocytes in vivo. Proc Natl Acad Sci USA 92: 6210-6214, 1995.
14. Liu Y. Hepatocyte growth factor and the kidney. Curr Opin Nephrol Hypertens 11: 23-30, 2002.
15. Liu Y. Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action. Am J Physiol Renal Physiol 287: F7-F16, 2004.
16. Matsuo S, Lopez-Guisa JM, Cai X, Okamura DM, Alpers CE, Bumgarner RE, Peters MA, Zhang G, Eddy AA. Multifunctionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1-overexpressing mice. Kidney Int 67: 2221-2238, 2005.
17. McGuire PG, Jones TR, Talarico N, Warren E, Das A. The urokinase/urokinase receptor system in retinal neovascularization: inhibition by A6 suggests a new therapeutic target. Invest Ophthalmol Vis Sci 44: 2736-2742, 2003.
18. Miranda-Diaz A, Rincon AR, Salgado S, Vera-Cruz J, Galvez J, Islas MC, Berumen J, Aguilar-Cordova E, Armendariz-Borunda J. Improved effects of viral gene delivery of human uPA plus biliodigestive anastomosis induce recovery from experimental biliary cirrhosis. Mol Ther 9: 30-37, 2004.
19. Mizuno S, Matsumoto K, Nakamura T. Hepatocyte growth factor suppresses interstitial fibrosis in a mouse model of obstructive nephropathy. Kidney Int 59: 1304-1314, 2001.
20. Mondino A, Blasi F. uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol 25: 450-455, 2004.
21. Moriwaki H, Stempien-Otero A, Kremen M, Cozen AE, Dichek DA. Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice. Circ Res 95: 637-644, 2004.
22. Naldini L, Vigna E, Bardelli A, Follenzi A, Galimi F, Comoglio PM. Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. J Biol Chem 270: 603-611, 1995.
23. Nassar T, Haj-Yehia A, Akkawi S, Kuo A, Bdeir K, Mazar A, Cines DB, Higazi AA. Binding of urokinase to low density lipoprotein-related receptor (LRP) regulates vascular smooth muscle cell contraction. J Biol Chem 277: 40499-40504, 2002.
24. Oda T, Jung YO, Kim HS, Cai X, Lopez-Guisa JM, Ikeda Y, Eddy AA. PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int 60: 587-596, 2001.
25. Sappino AP, Huarte J, Vassalli JD, Belin D. Sites of synthesis of urokinase and tissue-type plasminogen activators in the murine kidney. J Clin Invest 87: 962-970, 1991.
26. Sisson TH, Hanson KE, Subbotina N, Patwardhan A, Hattori N, Simon RH. Inducible lung-specific urokinase expression reduces fibrosis and mortality after lung injury in mice. Am J Physiol Lung Cell Mol Physiol 283: L1023-L1032, 2002.
27. Sisson TH, Hattori N, Xu Y, Simon RH. Treatment of bleomycininduced pulmonary fibrosis by transfer of urokinase-type plasminogen activator genes. Hum Gene Ther 10: 2315-2323, 1999.
28. Yang J, Liu Y. Delayed administration of hepatocyte growth factor reduces renal fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol 284: F349-F357, 2003.
29. Yang J, Shultz RW, Mars WM, Wegner RE, Li Y, Dai C, Nejak K, Liu Y. Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy. J Clin Invest 110: 1525-1538, 2002.
30. Zhang G, Cai X, Lopez-Guisa JM, Collins SJ, Eddy AA. Mitogenic signaling of urokinase receptor-deficient kidney fibroblasts: actions of an alternative urokinase receptor and LDL receptor-related protein. J Am Soc Nephrol 15: 2090-2102, 2004.
31. Zhang G, Kernan KA, Collins SJ, Cai X, Lopez-Guisa JM, Degen JL, Shvil Y, Eddy AA. Plasmin(ogen) promotes renal interstitial fibrosis by promoting epithelial-to-mesenchymal transition: role of plasmin-activated signals. J Am Soc Nephrol In press.
32. Zhang G, Kim H, Cai X, Lopez-Guisa JM, Alpers CE, Liu Y, Carmeliet P, Eddy AA. Urokinase receptor deficiency accelerates renal fibrosis in obstructive nephropathy. J Am Soc Nephrol 14: 1254-1271, 2003.
33. Zhang G, Kim H, Cai X, Lopez-Guisa JM, Carmeliet P, Eddy AA. Urokinase receptor modulates cellular and angiogenic responses in obstructive nephropathy. J Am Soc Nephrol 14: 1234-1253, 2003.